Vitro Launches New Stem Cell Products for Clinical Use & Presents Webinar with HemoGenix®, Inc.

GOLDEN, Colo.--(BUSINESS WIRE)-- Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of several new stem cell products including those with application to clinical studies. The new products were presented to the scientific community in a webinar jointly produced with our strategic partner, HemoGenix®, Inc. entitled “Mesenchymal Stem/Stromal Cells: Advances in Assays and Growth/Differentiation Media.” Vitro’s catalog now consists of adult stem cells, their fluorescent derivatives, and an expanded menu of tools for cellular reprogramming of adult cells to the functional equivalent of embryonic stem cells. Vitro now offers several additional formulations of its highly competitive MSCGro™ stem cell media product line together with advanced analytical tools, jointly manufactured with HemoGenix®, Inc., for the determination of stem cell quality, potency and response to toxic agents.

Dr. Jim Musick, Vitro’s president and CEO, said, “We are pleased to announce our new 2011 Catalog that features several new products for use in the advancement of adult stem cell research and clinical applications. Our products are focused on mesenchymal stem cells (MSCs) that are a type of adult stem cell present in several tissues with numerous clinical applications including bone, tendon and cartilage repair; treatment of heart, lung and kidney failure, treatment of autoimmune diseases, and numerous additional applications in regenerative medicine and treatment of other diseases. We have introduced clinical grade cell culture medium for the expansion of MSCs prior to use in therapeutic applications. This media is chemically defined and contains neither animal components nor serum, which is required for approval by regulatory agencies including the FDA. We also now provide dried MSC media that greatly reduces delivery costs to our foreign customers. As we develop our global business, the ability to cut importation costs adds to the numerous competitive advantages of our products thus increasing our market opportunities considerably.”

About HemoGenix®, Inc.

HemoGenix®, (http://www.hemogenix.com/) a privately held life sciences company located in Colorado Springs, Colorado was founded in 2000 by Ivan N. Rich, Ph.D., an internationally recognized researcher in the field of developmental, experimental and applied clinical hematology. HemoGenix® was formed as a Contract Research Service Laboratory for stem cell hemotoxicity testing. Dr. Rich subsequently developed, patented and commercialized the HALO® Assay Platform, a state-of-the art quantitative assay for hematopoietic stem cells. The HALO® Assay replaces the older colony-forming assay for stem cells which has many disadvantages including variable results resulting in a lack of quantization.

HemoGenix®, Inc now offers over 1,000 different catalog items including, HALO®, LUMENESC™ and LumiSTEM™ Kits all over the world to biotechnology and pharmaceutical companies and academic institutions.

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG) (http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute LUMENESC™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

Vitro Diagnostics, Inc.
Dr. James Musick
Chief Executive Officer
303-999-2130
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Genetics  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.